450 followers
RT @EEconAES: Cost-utility of denosumab for the treatment of postmenopausal #osteoporosis in Spain @josepdarba http://t.co/Dx8GGIg2kW @Amgen
RT @EEconAES: Cost-utility of denosumab for the treatment of postmenopausal #osteoporosis in Spain @josepdarba http://t.co/Dx8GGIg2kW @Amgen
High #fracture_risk (>75 yrs with fracture or T-score ≤-3.5): #denosumab was cost-saving compared vs alendronate http://t.co/JK0qwj2DWX
High #fracture_risk (>75 yrs with fracture or T-score ≤-3.5): #denosumab was cost-saving compared vs alendronate http://t.co/JK0qwj2DWX
#Fracture_prevention: #denosumab cost-effective vs #alendronate,#risedronate, #ibandronate (Spain) http://t.co/JK0qwj2DWX